TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on March 5, 2019, covering events occurring on February 28, 2019, and March 1, 2019. The filing discloses the entry into two material definitive agreements: a term loan facility with Hercules Capital, Inc., and an underwriting agreement for a public equity offering with Cantor Fitzgerald & Co.
Key Financial Metrics and Agreements
Debt Financing
- Total Facility: Up to $60.0 million term loan.
- Initial Draw: $30.0 million drawn on February 28, 2019.
- Future Advances: Two $10.0 million advances subject to clinical milestones; one $10.0 million advance available through December 15, 2020, subject to investment committee approval.
- Interest Rate: Greater of (Prime Rate + 4.75%) or 10.25% per annum.
- Repayment Terms: Interest-only payments until October 1, 2020 (potentially extendable to April 1, 2021). Principal amortization over 18 months (or 12 months if extended).
- Maturity Date: March 1, 2022.
- Final Payment: 3.5% of the aggregate principal amount due on maturity.
- Prepayment Penalties: 3.0% (first 12 months), 1.5% (months 13-24), 0% thereafter.
- Collateral: Lien on substantially all assets excluding intellectual property.
- Warrant Coverage: 2% of total funded amount (147,058 shares at $4.08 exercise price).
Equity Financing
- Shares Sold: 4,100,000 firm shares plus 615,000 option shares (fully exercised).
- Gross Proceeds: Approximately $27.7 million.
- Underwriter: Cantor Fitzgerald & Co. (sole book-running manager).
- Expected Closing: March 5, 2019.
- Offering Expenses: Total estimated expenses of $170,000 (Legal: $100,000; Accountants: $50,000; Transfer Agent: $5,000; Miscellaneous: $15,000).
Material Changes and Use of Proceeds
The filing represents a significant change in the company's capital structure through the addition of $30.0 million in immediate debt and approximately $27.7 million in equity capital. Proceeds from the term loan are designated for ongoing research and development programs and general corporate purposes. The equity offering proceeds are intended to support the company's operations, though specific allocation beyond general corporate purposes is not detailed in this summary.
Outlook, Risks, and Contingencies
- Covenants: The Loan Agreement includes customary covenants regarding liquidity, financial reporting, and limitations on dividends, indebtedness, and mergers.
- Events of Default: Include failure to make payments, breach of covenants, material adverse effect, insolvency, or material defaults on other indebtedness exceeding $750,000.
- Extension Conditions: The interest-only period may be extended if the company achieves a specific clinical milestone or raises at least $150.0 million in unrestricted net cash proceeds by September 30, 2020.
- Legal Disclaimer: Representations and warranties in the Underwriting Agreement are for the benefit of the parties to the agreement and should not be relied upon by investors as characterizations of the company's actual state of facts.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds of the equity offering (expected March 5, 2019).
- Confirm the exact interest rate applicable based on the Prime Rate at the time of funding.
- Review the specific clinical trial milestones required to trigger the additional $20.0 million in debt advances.
- Monitor the company's ability to meet the liquidity covenant and the $150.0 million fundraising threshold required to extend the interest-only period.
- Check subsequent filings for the final prospectus supplement to confirm the exact share price and underwriting discounts.